Eli Lilly CDR (CAD Hedged)

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Comparison of Two Doses of Pemetrexed in Patients Who Have Lung Cancer

Phase 3

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: pemetrexed

First Posted Date: 2004-02-24

Last Posted Date: 2019-09-12

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 589

Registration Number: NCT00078260

Locations: 🇹🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gaziantep, Turkey

Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

First Posted Date: 2004-02-12

Last Posted Date: 2012-06-07

Lead Sponsor: Eli Lilly and Company

Registration Number: NCT00006459

Locations: 🇺🇸
Comprehensive Cancer Institute of Huntsville, Huntsville, Alabama, United States
🇺🇸
Little Rock Hematology-Oncology Associates, Little Rock, Arkansas, United States
🇺🇸
Pacific Coast Hematology/Oncology Medical Group, Fountain Valley, California, United States

and more 28 locations

New Oral Anticoagulant Therapy for the Prevention of Blood Clots Following Hip or Knee Replacement Surgery

Phase 2

Completed

Conditions: Total Knee Replacement
Total Hip Replacement

Interventions: Drug: LY517717
Drug: enoxaparin

First Posted Date: 2003-12-23

Last Posted Date: 2008-03-31

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 511

Registration Number: NCT00074828

Locations: 🇵🇱
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Bydgoszcz, Poland

Duloxetine Compared to Escitalopram and Placebo in the Treatment of Patients With Depression

Phase 3

Completed

Conditions: Depression

First Posted Date: 2003-11-21

Last Posted Date: 2007-07-31

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 675

Registration Number: NCT00073411

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Cincinnati, Ohio, United States

Pemetrexed and Carboplatin in Locally Advanced or Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer
Neoplasm Metastasis

First Posted Date: 2003-11-13

Last Posted Date: 2007-01-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 50

Registration Number: NCT00072865

Locations: 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Saint Petersburg, Russia, Russian Federation

Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial

Conditions: Major Depressive Disorder
Fibromyalgia
Diabetic Peripheral Neuropathic Pain
Generalized Anxiety Disorder

First Posted Date: 2003-10-30

Last Posted Date: 2025-01-10

Lead Sponsor: Eli Lilly and Company

Registration Number: NCT00071708

Locations: 🇦🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Perth, Western Australia, Australia

Duloxetine vs. Active Comparator in the Treatment of Patients With Depression

Phase 4

Completed

Conditions: Depression

First Posted Date: 2003-10-30

Last Posted Date: 2007-05-21

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 320

Registration Number: NCT00071695

Locations: 🇫🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5 PM Easter Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Rochelle, France

Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Lung Neoplasms

First Posted Date: 2003-10-16

Last Posted Date: 2007-01-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 48

Registration Number: NCT00071136

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY(1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC-GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States

A Study With Gemcitabine, Cisplatin, and LY293111 in Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

First Posted Date: 2003-10-06

Last Posted Date: 2007-12-21

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 195

Registration Number: NCT00069875

Locations: 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Madrid, Spain
🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician, Montreal, Quebec, Canada

Duloxetine vs. Active Comparator for the Treatment of Depression

Phase 4

Completed

Conditions: Depression

First Posted Date: 2003-09-03

Last Posted Date: 2007-05-21

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 480

Registration Number: NCT00067912

Locations: 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Calgary, Alberta, Canada

AI-Powered Research

Premium Access

Eli Lilly CDR (CAD Hedged)

A Comparison of Two Doses of Pemetrexed in Patients Who Have Lung Cancer

Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer

New Oral Anticoagulant Therapy for the Prevention of Blood Clots Following Hip or Knee Replacement Surgery

Duloxetine Compared to Escitalopram and Placebo in the Treatment of Patients With Depression

Pemetrexed and Carboplatin in Locally Advanced or Metastatic Breast Cancer

Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial

Duloxetine vs. Active Comparator in the Treatment of Patients With Depression

Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

A Study With Gemcitabine, Cisplatin, and LY293111 in Non-Small Cell Lung Cancer

Duloxetine vs. Active Comparator for the Treatment of Depression